DEL is different from “double-hit lymphoma” (DHL), which refers to lymphoma with BCL2, MYC or BCL6 gene rearrangements, but DEL is also predictive of tumors with high metabolic activity, inhibition of apoptosis, and risk of treatment resistance. This evidence concerns the gene MYC and lymphoma.